Bluejay Diagnostics, Inc.(BJDX)Earnings, Financials & Key Ratios
BJDX•NASDAQ
$1.89
$346611 mkt cap·Price updated May 6, 2026
AboutBluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.Show more
- Revenue$0
- EBITDA-$7M+26.9%
- Net Income-$8M+22.5%
- EPS (Diluted)-42.08+42.1%
- ROE-178.98%-29.8%
- ROIC-399.92%+23.5%
- Debt/Equity0.04-68.2%
- Interest Coverage-8.71
BJDX Key Insights
Bluejay Diagnostics, Inc. (BJDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Shares diluted 33.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BJDX Price & Volume
Bluejay Diagnostics, Inc. (BJDX) stock price & volume — 10-year historical chart
Loading chart...
BJDX Growth Metrics
Bluejay Diagnostics, Inc. (BJDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM20.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.24%
Return on Capital
10 Years-3489.69%
5 Years-4091.66%
3 Years-118.59%
Last Year-160.32%
BJDX Peer Comparison
Bluejay Diagnostics, Inc. (BJDX) competitors in Patient monitoring and wearable diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 QDEL | 746.18M | 10.96 | -0.66 | -1.89% | -45.57% | -56.31% | 1.46 | |
 CUE | 89.3M | 33.98 | -4.05 | 195.75% | -96.85% | -165.19% | 0.16 | |
 LFMD | 252.82M | 5.27 | -22.91 | -8.66% | -7.76% | -162.38% | 0.27 | |
 IDXX | 46.12B | 579.23 | 44.28 | 10.42% | 24.63% | 70.87% | 0.67 | |
 OSUR | 215.9M | 3.00 | -3.19 | -38.1% | -61.93% | -19.46% | 0.04 | |
 CHEK | 12.17M | 2.08 | -0.48 | -226.19% | ||||
 TNXP | 33.25M | 14.69 | -0.08 | 29.94% | -9.63% | -42.93% | 0.04 | |
 DHR | 123.8B | 174.92 | 34.71 | 2.9% | 14.89% | 7.06% | 0.35 |
Compare BJDX vs Peers
Bluejay Diagnostics, Inc. (BJDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BJDX Income Statement
Bluejay Diagnostics, Inc. (BJDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 249.04K | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | -100% | - | - |
| Cost of Goods Sold | 142.97K | 157.04K | 145.72K | 200.13K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | 80.36% | - | - | - |
| Gross Profit | -142.97K▲ 0% | -157.04K▼ 9.8% | -145.72K▲ 7.2% | 48.91K▲ 133.6% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | 19.64% | - | - | - |
| Gross Profit Growth % | - | -9.84% | 7.21% | 133.57% | -100% | - | - |
| Operating Expenses | 1.63M | 1.04M | 3.08M | 9.37M | 10.31M | 7.17M | 6.98M |
| OpEx % of Revenue | - | - | - | 3761.12% | - | - | - |
| Selling, General & Admin | 1.18M | 669.14K | 2.08M | 5.21M | 4.6M | 3.7M | 3.96M |
| SG&A % of Revenue | - | - | - | 2093.85% | - | - | - |
| Research & Development | 454.61K | 527.25K | 1.15M | 4.15M | 5.71M | 3.47M | 3.01M |
| R&D % of Revenue | - | - | - | 1667.26% | - | - | - |
| Other Operating Expenses | 0 | -157.04K | -145.72K | 0 | 0 | 0 | 0 |
| Operating Income | -1.63M▲ 0% | -1.2M▲ 26.7% | -3.23M▼ 170.0% | -9.32M▼ 188.5% | -10.31M▼ 10.7% | -7.17M▲ 30.5% | -6.98M▲ 0% |
| Operating Margin % | - | - | - | -3741.48% | - | - | - |
| Operating Income Growth % | - | 26.67% | -169.99% | -188.46% | -10.66% | 30.47% | - |
| EBITDA | -1.49M | -1.04M | -3.08M | -9.01M | -9.53M | -6.97M | -6.84M |
| EBITDA Margin % | - | - | - | -3618.46% | - | - | - |
| EBITDA Growth % | - | 30.17% | -196.77% | -192.16% | -5.76% | 26.86% | 12.94% |
| D&A (Non-Cash Add-back) | 142.97K | 157.04K | 145.72K | 306.37K | 780.96K | 199.1K | 138.35K |
| EBIT | -1.63M | -1.2M | -3.23M | -9.32M | -9.95M | -6.89M | -6.87M |
| Net Interest Income | 52.28K | 116.67K | 145.84K | 89.67K | 164.9K | -677.21K | 210.69K |
| Interest Income | 52.28K | 143.67K | 513.3K | 89.67K | 164.9K | 145.82K | 211.84K |
| Interest Expense | - | 27K | 367.46K | 0 | 0 | 823.03K | 1.15K |
| Other Income/Expense | 811.57K | 38.11K | -258.13K | 20.83K | 357.33K | -548.18K | 125.21K |
| Pretax Income | -819.84K▲ 0% | -1.16M▼ 41.3% | -3.49M▼ 201.2% | -9.3M▼ 166.5% | -9.95M▼ 7.1% | -7.72M▲ 22.5% | -6.85M▲ 0% |
| Pretax Margin % | - | - | - | -3733.11% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -757.72K▲ 0% | -1.13M▼ 48.6% | -3.73M▼ 231.3% | -9.3M▼ 149.3% | -9.95M▼ 7.1% | -7.72M▲ 22.5% | -6.85M▲ 0% |
| Net Margin % | - | - | - | -3733.11% | - | - | - |
| Net Income Growth % | - | -48.57% | -231.32% | -149.27% | -7.07% | 22.46% | 20.23% |
| Net Income (Continuing) | -819.84K | -1.16M | -3.49M | -9.3M | -9.95M | -7.72M | -6.85M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -9.55▲ 0% | -14.19▼ 48.6% | -29.67▼ 109.1% | -73.22▼ 146.8% | -72.62▲ 0.8% | -42.08▲ 42.1% | -4.35▲ 0% |
| EPS Growth % | - | -48.59% | -109.09% | -146.78% | 0.82% | 42.05% | 59.24% |
| EPS (Basic) | -9.55 | -14.19 | -29.67 | -73.22 | -72.62 | -42.08 | - |
| Diluted Shares Outstanding | 79.34K | 79.34K | 125.7K | 126.02K | 137.06K | 183.39K | 1.57M |
| Basic Shares Outstanding | 79.34K | 79.34K | 125.7K | 126.02K | 137.06K | 183.39K | 1.57M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
BJDX Balance Sheet
Bluejay Diagnostics, Inc. (BJDX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 300.34K | 1.06M | 20.66M | 11.79M | 3.22M | 4.9M | 3.35M |
| Cash & Short-Term Investments | 96.01K | 912.36K | 19.05M | 10.11M | 2.21M | 4.3M | 3.08M |
| Cash Only | 96.01K | 912.36K | 19.05M | 10.11M | 2.21M | 4.3M | 3.08M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 645 | 0 | 0 | 0 | 41.27K | 14.56K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 123.51K | 84.76K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 315.3 | 197.01 | - | - | - | - | - |
| Other Current Assets | 69.92K | 0 | 0 | 0 | 223.81K | -14.56K | 101.17K |
| Total Non-Current Assets | 616.18K | 459.14K | 358.38K | 1.73M | 1.65M | 1.76M | 1.54M |
| Property, Plant & Equipment | 611.56K | 459.14K | 332.75K | 1.7M | 1.62M | 1.72M | 1.53M |
| Fixed Asset Turnover | - | - | - | 0.15x | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4.62K | 4.62K | 4.62K | 4.46K | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | -4.62K | 21.02K | 30.75K | 28.66K | 35.26K | 100.58K |
| Total Assets | 916.52K▲ 0% | 1.52M▲ 65.6% | 21.02M▲ 1285.3% | 13.52M▼ 35.7% | 4.87M▼ 64.0% | 6.66M▲ 36.7% | 4.89M▲ 0% |
| Asset Turnover | - | - | - | 0.02x | - | - | 0.00x |
| Asset Growth % | - | 65.55% | 1285.25% | -35.67% | -63.99% | 36.74% | -41.75% |
| Total Current Liabilities | 576.54K | 1.85M | 637.16K | 1.64M | 1.77M | 810.37K | 1.15M |
| Accounts Payable | 29.13K | 374.93K | 295.78K | 635.82K | 491.47K | 145.12K | 161.16K |
| Days Payables Outstanding | 74.35 | 871.43 | 740.87 | 1.16K | - | - | - |
| Short-Term Debt | 265K | 1.06M | 0 | 0 | 0 | 113.26K | 0 |
| Deferred Revenue (Current) | 86K | 258.92K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 196.41K | 21.81K | 0 | 4.81K | 4.81K | 4.81K | 0 |
| Current Ratio | 0.52x | 0.57x | 32.43x | 7.19x | 1.82x | 6.05x | 6.05x |
| Quick Ratio | 0.31x | 0.53x | 32.43x | 7.19x | 1.82x | 6.05x | 6.05x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 3.27M | 3.88M | 0 | 339.74K | 202.31K | 117.56K | 48.56K |
| Long-Term Debt | 804.29K | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 323.92K | 189.99K | 108.99K | 311.31K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.47M | 3.88M | 0 | 15.82K | 12.32K | 8.57K | 21.72K |
| Total Liabilities | 3.85M | 5.72M | 637.16K | 1.98M | 1.97M | 927.92K | 1.2M |
| Total Debt | 1.07M | 1.06M | 0 | 492.62K | 352.98K | 222.25K | 142.99K |
| Net Debt | 973.28K | 143.55K | -19.05M | -9.62M | -1.86M | -4.08M | -2.94M |
| Debt / Equity | - | - | - | 0.04x | 0.12x | 0.04x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | -0.02x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.43x |
| Interest Coverage | - | -44.32x | -8.79x | - | - | -8.71x | -5972.19x |
| Total Equity | -2.93M▲ 0% | -4.21M▼ 43.4% | 20.38M▲ 584.6% | 11.54M▼ 43.4% | 2.89M▼ 74.9% | 5.73M▲ 97.9% | 3.69M▲ 0% |
| Equity Growth % | - | -43.44% | 584.57% | -43.37% | -74.92% | 97.92% | 25.51% |
| Book Value per Share | -36.96 | -53.02 | 162.14 | 91.58 | 21.12 | 31.24 | 2.35 |
| Total Shareholders' Equity | -2.93M | -4.21M | 20.38M | 11.54M | 2.89M | 5.73M | 3.69M |
| Common Stock | 315 | 315 | 2.01K | 2.02K | 124 | 55 | 164 |
| Retained Earnings | -2.93M | -4.21M | -7.69M | -17M | -26.95M | -34.67M | -40.09M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.47M | -3.88M | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BJDX Cash Flow Statement
Bluejay Diagnostics, Inc. (BJDX) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.69M | -508.71K | -4.37M | -7.74M | -8.31M | -7.82M | -7.82M |
| Operating CF Margin % | - | - | - | -3108.57% | - | - | - |
| Operating CF Growth % | - | 69.9% | -758.4% | -77.28% | -7.39% | 5.94% | 105.75% |
| Net Income | -819.84K | -1.16M | -3.49M | -9.3M | -9.95M | -7.72M | -6.85M |
| Depreciation & Amortization | 142.97K | 157.04K | 145.72K | 306.37K | 780.96K | 199.1K | 159.35K |
| Stock-Based Compensation | 14.81K | 7.37K | 68.46K | 433K | 189.25K | 20.09K | -251 |
| Deferred Taxes | 0 | 0 | 170.66K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -849.78K | -111.1K | 222.01K | 237.45K | 3.09K | 312.03K | -511.66K |
| Working Capital Changes | -178.28K | 596.26K | -1.49M | 578.54K | 666.73K | -633.19K | 865.83K |
| Change in Receivables | -645 | 645 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -103.88K | 38.75K | 84.76K | 0 | 0 | 0 | 0 |
| Change in Payables | -25.21K | 345.8K | -79.15K | 298.88K | -235.76K | -346.35K | 4.82K |
| Cash from Investing | -6.02K | 0 | -23.95K | -1.2M | -704.17K | -306.78K | -1.13K |
| Capital Expenditures | -6.02K | 0 | -23.95K | -1.2M | -704.17K | -306.78K | -1.13K |
| CapEx % of Revenue | - | - | - | 481.56% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.51M | 1.33M | 22.53M | 8.07K | 1.11M | 10.22M | 3.67M |
| Debt Issued (Net) | -265K | 270K | 4.2M | -801 | -4.81K | -4.81K | 283.38K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 8.88K | 159.84K | 1000K | 1M |
| Dividends Paid | 0 | 0 | -17.67K | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 100K | 0 | -513.47K | 0 | 956.53K | -1.84M | -465.06K |
| Net Change in Cash | -184.34K▲ 0% | 816.35K▲ 542.9% | 18.14M▲ 2121.5% | -8.93M▼ 149.3% | -7.91M▲ 11.5% | 2.09M▲ 126.5% | -2.67M▲ 0% |
| Free Cash Flow | -1.7M▲ 0% | -508.71K▲ 70.0% | -4.39M▼ 763.1% | -8.94M▼ 103.6% | -9.02M▼ 0.9% | -8.13M▲ 9.9% | -6.34M▲ 0% |
| FCF Margin % | - | - | - | -3590.13% | - | - | - |
| FCF Growth % | - | 70.01% | -763.11% | -103.63% | -0.86% | 9.89% | 31.49% |
| FCF per Share | -21.38 | -6.41 | -34.93 | -70.95 | -65.79 | -44.31 | -44.31 |
| FCF Conversion (FCF/Net Income) | 2.23x | 0.45x | 1.17x | 0.83x | 0.84x | 1.01x | 0.93x |
| Interest Paid | 46.07K | 53.24K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BJDX Key Ratios
Bluejay Diagnostics, Inc. (BJDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -46.12% | -58.25% | -137.9% | -178.98% | -185.51% |
| Return on Invested Capital (ROIC) | - | - | -429.68% | -522.84% | -399.92% | -399.92% |
| Gross Margin | - | - | 19.64% | - | - | - |
| Net Margin | - | - | -3733.11% | - | - | - |
| Debt / Equity | - | - | 0.04x | 0.12x | 0.04x | 0.04x |
| Interest Coverage | -44.32x | -8.79x | - | - | -8.71x | -5972.19x |
| FCF Conversion | 0.45x | 1.17x | 0.83x | 0.84x | 1.01x | 0.93x |
| Revenue Growth | - | - | - | -100% | - | - |
BJDX Frequently Asked Questions
Bluejay Diagnostics, Inc. (BJDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bluejay Diagnostics, Inc. (BJDX) grew revenue by 0.0% over the past year. Growth has been modest.
Bluejay Diagnostics, Inc. (BJDX) reported a net loss of $6.9M for fiscal year 2024.
Dividend & Returns
Bluejay Diagnostics, Inc. (BJDX) has a return on equity (ROE) of -179.0%. Negative ROE indicates the company is unprofitable.
Bluejay Diagnostics, Inc. (BJDX) had negative free cash flow of $6.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More BJDX
Bluejay Diagnostics, Inc. (BJDX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates